6
MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias

https://doi.org/10.1016/j.beha.2009.05.003Get rights and content

Altered expression of microRNAs, a new class of noncoding RNAs that regulate messenger RNA and protein expression of target genes, has been recently demonstrated to have an essential role in the process of leukaemogenesis. Distinctive patterns of activation and/or silencing of multiple microRNAs (microRNA signatures) associated with certain cytogenetic and molecular subsets of leukaemia have been identified using genome-wide high-throughput profiling assays. This has led not only to the discovery of new molecular pathways implicated in leukaemogenesis, but also supplied prognostic information complementing that gained from cytogenetics, gene mutations and altered gene expression in acute and chronic leukaemias. We review herein results of current studies analysing changes of microRNA expression in acute myeloid leukaemia and chronic lymphocytic leukaemia, and discuss their potential biologic, diagnostic and prognostic relevance.

Section snippets

Acute myeloid leukaemia

Acute myeloid leukaemia (AML) is a heterogeneous group of neoplastic haematopoietic diseases characterised by proliferation and maturation arrest of myeloid blasts in bone marrow and blood [10]. In spite of recent improvements in our understanding of AML, leukaemogenesis and the application of more aggressive therapies, the prognosis of the majority of patients with AML is still poor. The long-term overall survival (OS) rate for AML patients under the age of 60 years is only 30–40%, whereas the

Genetic alterations as prognostic factors in AML

Of the several factors that predict clinical outcome and are used to stratify AML patients to different treatment approaches, cytogenetic findings at diagnosis are among the most important [12], [13], [14], [15], [16], [17]. Patients with t(8;21)(q22;q22) or inv(16)(p13q22) or t(16;16)(p13;q22), aberrations characteristic of core-binding factor AML (CBF-AML), and those with t(15;17)(q22;q12∼q21), a translocation typical of acute promyelocytic leukaemia (APL), have a relatively good outcome. On

Correlations with morphologic, cytogenetic and molecular features

More recently, abnormalities of expression of multiple miRNAs in AML have been reported. Akin to a landmark study, which demonstrated that gene-expression profiling can distinguish between AML and ALL [38], Mi et al. [39] showed that the same could be achieved using miRNA-expression profiling. In this study, patients with AML could be separated from those with ALL on the basis of 21 up-regulated (i.e., let-7a, let-7b, let-7c, let-7e, miR-21, miR-22, miR-23a, miR-23b, miR-24, miR-26a, miR-27a,

Chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) accounts for around 30% of leukaemia cases in the United States of America, with the highest incidence in the elderly population [57]. The age-adjusted incidence rate of CLL is 4.0 per 100 000 men and women per year [58].

The disease is characterised by the progressive accumulation of clonal CD5-positive B lymphocytes in the blood, bone marrow and lymphatic tissues. It has been demonstrated that over 90% of leukaemic cells are non-dividing and resistant to

miRNAs in chronic lymphocytic leukaemia

Several cytogenetic aberrations have been shown to be independent predictors of disease progression and survival [61]. Among them, deletions of chromosome 13 at band 13q14.3, which are detected by fluorescence in situ hybridisation (FISH) in approximately 55% of CLL cases, have been associated with a better outcome [61]. Deletions of 13q14.3 have also been observed in other types of cancer including mantle cell lymphoma, multiple myeloma and other lymphoid neoplasms, prostate cancer and

Conclusions

Deregulated miRNA expression has been associated with cytogenetic and molecular abnormalities, and pre-treatment clinical features and outcomes in acute and chronic leukaemias. Although the process of discovering functional interactions between alterations in miRNA expression and other leukaemia characteristics has just begun, examination of miRNA expression, together with array-based comparative genomic hybridisation, single nucleotide polymorphism array analyses, gene-expression profiling

Conflict of interest statement

The authors report no conflicts of interest.

Acknowledgements

This work is supported in part by National Cancer Institute, Bethesda, Maryland (MD) grants CA16058 and R01CA102031, and the Coleman Leukemia Research Foundation.

References (87)

  • K. Mrózek et al.

    Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

    Blood

    (2007)
  • C. Langer et al.

    High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

    Blood

    (2008)
  • M. Heuser et al.

    High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

    Blood

    (2006)
  • K. Döhner et al.

    Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

    Blood

    (2005)
  • R. Cairoli et al.

    Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

    Blood

    (2006)
  • B.J. Wouters et al.

    A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects

    Blood

    (2009)
  • M.D. Radmacher et al.

    Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study

    Blood

    (2006)
  • K.H. Metzeler et al.

    An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

    Blood

    (2008)
  • L. Bullinger et al.

    Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

    Blood

    (2007)
  • M. Jongen-Lavrencic et al.

    MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia

    Blood

    (2008)
  • R. Garzon et al.

    MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

    Blood

    (2008)
  • R. Popovic et al.

    Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization

    Blood

    (2009)
  • M. Alcalay et al.

    Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance

    Blood

    (2005)
  • R.G.W. Verhaak et al.

    Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

    Blood

    (2005)
  • M.L. Choong et al.

    MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis

    Exp Hematol

    (2007)
  • G. Dighiero et al.

    Chronic lymphocytic leukaemia

    Lancet

    (2008)
  • Y. Liu et al.

    13q deletions in lymphoid malignancies

    Blood

    (1995)
  • S. Kitada et al.

    Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses

    Blood

    (1998)
  • M. Sánchez-Beato et al.

    Cell cycle deregulation in B-cell lymphomas

    Blood

    (2003)
  • E.S. Raveche et al.

    Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice

    Blood

    (2007)
  • R.L. Browning et al.

    Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

    Leuk Res

    (2007)
  • A.J. Johnson et al.

    Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

    Blood

    (2006)
  • M. Yang et al.

    Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs

    Pharmacol Ther

    (2008)
  • V. Ambros

    The functions of animal microRNAs

    Nature

    (2004)
  • R.I. Gregory et al.

    MicroRNA biogenesis and cancer

    Cancer Res

    (2005)
  • G.A. Calin et al.

    MicroRNA signatures in human cancers

    Nat Rev Cancer

    (2006)
  • G.A. Calin et al.

    Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers

    Proc Natl Acad Sci U S A

    (2004)
  • R. Garzon et al.

    MicroRNAs in normal and malignant hematopoiesis

    Curr Opin Hematol

    (2008)
  • Fabbri M, Croce CM, Calin GA. MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma...
  • T.-C. Chang et al.

    Widespread microRNA repression by Myc contributes to tumorigenesis

    Nat Genet

    (2008)
  • E.H. Estey

    Treatment of acute myeloid leukemia

    Haematologica

    (2009)
  • S. Fröhling et al.

    Chromosomal abnormalities in cancer

    N Engl J Med

    (2008)
  • S.S. Farag et al.

    Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

    J Clin Oncol

    (2005)

    • Cited by (25)

    • Role of post-transcriptional gene regulation in hematological malignancies

      2022, Post-transcriptional Gene Regulation in Human Disease: Volume 32

    • Cancer cells stemness: A doorstep to targeted therapy

      2020, Biochimica et Biophysica Acta - Molecular Basis of Disease
      Citation Excerpt :

      The role of miRNAs in embryonic development and its association with stem cell functions was first identified with the discovery of two miRNAs lin-4 and let-7 in Caenorhabditis elegans [142,143]. Dysregulation of miRNAs is associated with various diseases including cancer [144,145]. CSCs are enriched with miRNAs which can be oncogenic or tumor-suppressive in nature.

    • The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis

      2011, European Journal of Cancer
      Citation Excerpt :

      MiR-29b induces global DNA hypomethylation and re-expression of tumour suppressor genes such as the CDK inhibitor p15INK4b and the oestrogen receptor ESR1 genes by targeting directly DNMT3A and 3B and indirectly DNMT1 through its activator Sp1.78 Nevertheless, overexpression of DNA methyltransferases isoforms may mediate aberrant hypermethylation and epigenetic silencing of tumour suppressor genes.79 MiR-29 is also down-regulated in other malignancies such as CLL,80 colon81 and breast52 cancers.

    • The prognostic and functional role of microRNAs in acute myeloid leukemia

      2011, Blood
      Citation Excerpt :

      Direct involvement of microRNAs in cancer has been suggested by a study demonstrating that several microRNAs are localized in genomic regions associated with cancer, such as breakpoint regions in chromosome aberrations involving oncogenes or tumor suppressor genes, minimal regions of loss of heterozygosity, minimal regions of amplification, and at loci close to fragile sites and integration sites of the human papilloma virus.10 Supporting their role in carcinogenesis, microRNAs mapped to the chromosomal regions deleted in cancer samples were found expressed at low levels,9 and several functional studies confirmed the important role of microRNA deregulation in hematologic malignancies, including acute myeloid leukemia (AML).9,11-19 Profiling and functional experiments revealed that several microRNAs play a role in the regulation of hematopoiesis.6-8

    • Role of Circulating MicroRNAs in Prognosis and Diagnosis of Cancers

      2022, Role of MicroRNAs in Cancers

    • Physiological fitness and the pathophysiology of chronic lymphocytic leukemia (Cll)

      2021, Cells
    View all citing articles on Scopus
    1

    These authors contributed equally to this work.

    View full text
    Copyright © 2009 Elsevier Ltd. All rights reserved.